Skip to main content
ALLR
NASDAQ Life Sciences

Allarity Q2: $26.9M Cash, $20M Debt, and a CLIA Lab Milestone

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$1.422
Mkt Cap
$21.639M
52W Low
$0.769
52W High
$2.35
52W Position info
85% above low
Off High info
39% below high
Rel. Volume info
1.0× avg
Market data snapshot near publication time

ALLR sits 85% above its 52-week low of $0.769.

Summary

Allarity reported Q2 2026 results with $26.9M in cash and restricted cash, a $3.4M net loss, and $20.9M in promissory note debt. The company also announced CLIA certification for its Denmark lab.


Key Events · Earnings and Guidance · ALLR

  • Q2 Net Loss of $3.4M

    Net loss for Q2 2026 was $3.4 million, compared to $2.3 million in Q2 2025. Operating expenses fell 35% to $2.7 million, but interest expense rose to $0.7 million due to the new promissory notes.

  • Cash Position at $26.9M

    Cash and restricted cash totaled $26.9 million as of June 30, 2026, including $10 million in restricted cash securing the B Note. Management expects this to fund operations for at least twelve months.

  • Streeterville Debt Totals $20.9M

    The March 2026 Streeterville notes have a total outstanding balance of $20.9 million, including a $1.97 million monitoring fee. The A-1 Note bears 9% interest and matures September 2, 2027.

  • Tumim Equity Line Nearly Untapped

    The $6.0 million Tumim equity line has only $2,000 drawn, leaving $5.998 million available. The purchase price is set at 95-97% of VWAP, subject to a 19.99% issuance limit.


Analysis · ALLR · Life Sciences

Allarity's Q2 2026 report shows a net loss of $3.4 million and a cash position of $26.9 million, including $10 million in restricted cash securing the Streeterville B Note. The company raised $20 million in March via promissory notes, but the A-1 Note carries a 9% interest rate and a $1.97 million monitoring fee, pushing total outstanding debt to $20.9 million. Management states cash is sufficient for at least twelve months, but the debt terms and ongoing losses keep liquidity risk elevated. The subsequent CLIA certification for the in-house lab is a positive operational step for stenoparib development.

How filings like this one have moved

In the 30 days to Nov 15, 2026, 37.5% of the 3713 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, ALLR was trading at $1.42 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $21.6M. The 52-week trading range was $0.77 to $2.35. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ALLR - Latest Insights

ALLR
Nov 13, 2026, 8:07 AM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $0.950
Real-time Price: $0.9949 info
Change: +$0.0449 (+5%) info
Market Cap: $15.176M info
ALLR
Nov 13, 2026, 8:05 AM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $0.950
Real-time Price: $0.9949 info
Change: +$0.0449 (+5%) info
Market Cap: $15.176M info
ALLR
Nov 02, 2026, 8:00 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.8415
Real-time Price: $0.9949 info
Change: +$0.1534 (+18%) info
Market Cap: $15.176M info
ALLR
Oct 30, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.870
Real-time Price: $0.9949 info
Change: +$0.1249 (+14%) info
Market Cap: $15.176M info
ALLR
Sep 14, 2026, 12:14 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.21
Real-time Price: $0.9949 info
Change: -$0.2151 (-18%) info
Market Cap: $15.176M info